Share this article on:

Impact of Autologous Dendritic Cell–Based Immunotherapy (AGS-004) on B- and T-Cell Subset Changes and Immune Activation in HIV-Infected Patients Receiving Antiretroviral Therapy

Jenabian, Mohammad-Ali DVM, PhD*; Nicolette, Charles A. PhD; Tcherepanova, Irina Y. PhD; DeBenedette, Mark A. PhD; Gilmore, Norbert MD, PhD*; Routy, Jean-Pierre MD*,‡

JAIDS Journal of Acquired Immune Deficiency Syndromes: 1 December 2013 - Volume 64 - Issue 4 - p 345–350
doi: 10.1097/QAI.0b013e3182a4b9ad
Brief Report: Basic and Translational Science

Abstract: We previously reported that a combination of antiretroviral therapy with 4 monthly injections of each patient's own autologous dendritic cells (AGS-004) electroporated with CD40 ligand and with HIV RNA antigens obtained from each patient's own pre-antiretroviral therapy plasma induced HIV-specific CD8 T-cell responses in 10 patients. To assess other AGS-004–induced immune changes, we evaluated the modifications in B- and T-cell subsets and the level of immune activation in these patients. The proportion of Bm1 naive cells was increased along with an augmentation of the proliferation marker Ki67. Memory B-cell frequency, CD4 and CD8 T-cell subsets, regulatory T-cell frequency, and CD38/HLA-DR/PD-1 T-cell activation levels remained unchanged after AGS-004 dendritic cell immunotherapy.

*Chronic Viral Illness Service and Research Institute, McGill University Health Centre, Montreal, Quebec, Canada;

Argos Therapeutics, Durham, NC; and

Division of Hematology, McGill University Health Centre, Montreal, Quebec, Canada.

Correspondence to: Jean-Pierre Routy, MD, Division of Hematology, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada (e-mail: jean-pierre.routy@mcgill.ca).

Supported in part by “Le Fonds de recherche du Québec—Santé”: Thérapie cellulaire and Le syndrome de l'immunodéficience acquise/maladies infectieuses networks, Québec, Canada, and by the Canadian Institutes of Health Research (CIHR; grant #103230) and CIHR Canadian HIV Trials Network (CTN 229). M.-A.J. is supported by a Canadian Foundation for AIDS Research/CTN Postdoctoral Fellowship Award. J.-P.R. is a holder of Louis Lowenstein Chair in Hematology and Oncology, McGill University.

C.A.N., I.Y.T., and M.A.D. are employed by Argos Therapeutics Inc. All other authors have no conflicts of interest to disclose.

Presented partially at the Keystone Symposium, Immunological Mechanisms of Vaccination, December 14, 2012, Ottawa, Ontario, Canada. Abstract #1075.

Received May 09, 2013

Accepted July 11, 2013

© 2013 by Lippincott Williams & Wilkins